down arrow

Biora Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US74319F3055
USD
0.00
0 (-100.0%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.001.60
Valuation
Technical
Day's Volume

CASH

40

Shareholding (Sep 2024)

FII

0.24%

Held by 10 FIIs

DII

97.33%

Held by 3 DIIs

Promoter

0.00%

How big is Biora Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Biora Therapeutics, Inc. has a market capitalization of 0.75 million, with net sales of 0.89 million and a net profit of -35.58 million over the last four quarters. As of Dec 23, the company reported shareholder's funds of -101.42 million and total assets of 31.21 million.

Market Cap: As of Jun 18, Biora Therapeutics, Inc. has a market capitalization of 0.75 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Biora Therapeutics, Inc. reported net sales of 0.89 million and a net profit of -35.58 million.<BR><BR>Balance Sheet Snapshot: As of Dec 23, the company reported shareholder's funds of -101.42 million and total assets of 31.21 million.

Read More

What does Biora Therapeutics, Inc. do?

22-Jun-2025

Biora Therapeutics, Inc. is a biotechnology company focused on developing molecular testing products and precision medicine. As of September 2024, it has a market cap of $0.75 million, with net sales of $0 million and a net loss of $22 million.

Overview: <BR>Biora Therapeutics, Inc. is a biotechnology company engaged in developing and commercializing molecular testing products and precision medicine within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Sep 2024) <BR>Most recent Net Profit: -22 Million (Quarterly Results - Sep 2024) <BR>Market-cap: USD 0.75 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.34 <BR>Return on Equity: 75.48% <BR>Price to Book: -0.01<BR><BR>Contact Details: <BR>Address: 4330 La Jolla Village Dr Ste 200, SAN DIEGO CA: 92122 <BR>Tel: ['1 760 4941555', '1 619 2282886'] <BR>Fax: 1 248 8481623 <BR>Website: https://www.progenity.com/

Read More

Who are in the management team of Biora Therapeutics, Inc.?

22-Jun-2025

As of March 2022, Biora Therapeutics, Inc.'s management team includes Dr. Harry Stylli as Chairman and CEO, along with independent directors Mr. Jeffrey Alter, Mr. John Bigalke, Mr. Jeffrey Ferrell, Dr. Brian Kotzin, and Dr. Samuel Nussbaum.

As of March 2022, the management team of Biora Therapeutics, Inc. includes Dr. Harry Stylli, who serves as the Chairman of the Board and Chief Executive Officer. Additionally, the board consists of several independent directors: Mr. Jeffrey Alter, Mr. John Bigalke, Mr. Jeffrey Ferrell, Dr. Brian Kotzin, and Dr. Samuel Nussbaum.

Read More

Is Biora Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of August 15, 2022, Biora Therapeutics, Inc. is considered overvalued and has a concerning investment outlook due to its extreme EV to Sales ratio of 36.76, negative financial metrics, and significant underperformance compared to the S&P 500.

As of 15 August 2022, the valuation grade for Biora Therapeutics, Inc. moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued, as evidenced by its extreme EV to Sales ratio of 36.76 and negative metrics across key financial ratios, including a Price to Book Value of -0.01 and an EV to EBITDA of -0.61. <BR><BR>In comparison to its peers, Biora's valuation metrics are starkly unfavorable; for instance, GeneDx Holdings Corp. has a P/E ratio of -63.58 and an EV to EBITDA of 166.66, while Personalis, Inc. shows a P/E of -6.55 and an EV to EBITDA of -6.66. The company's stock has underperformed significantly against the S&P 500, with a one-year return of -97.99% compared to the index's 10.26%. Overall, Biora Therapeutics, Inc. presents a concerning investment outlook based on its current financial ratios and peer comparisons.

Read More

Is Biora Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of July 18, 2025, Biora Therapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, including bearish daily moving averages and a year-to-date return of -100.0%, significantly underperforming the S&P 500's 12.22% return.

As of 18 July 2025, the technical trend for Biora Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are bearish, and the weekly KST is bearish, suggesting weakness in the short term. The RSI shows no signal on the weekly timeframe but is bullish on the monthly, which adds some mixed signals. Overall, the indicators point to a mildly bearish stance.<BR><BR>The company has experienced significant declines, with a year-to-date return of -100.0%, underperforming the S&P 500, which has returned 12.22% in the same period.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.34

stock-summary
Return on Equity

75.48%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Sep 2024)
Net Profit:
-22 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-100.0%
0%
-100.0%
6 Months
-100.0%
0%
-100.0%
1 Year
-100.0%
0%
-100.0%
2 Years
-100.0%
0%
-100.0%
3 Years
-100.0%
0%
-100.0%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

Biora Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Biora Therapeutics, Inc. technically bullish or bearish?

As of 18 July 2025, the technical trend for Biora Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are bearish, and the weekly KST is bearish, suggesting weakness in the short term. The RSI shows no signal on the weekly timeframe but is bullish on the monthly, which adds some mixed signals. Overall, the indicators point to a mildly bearish stance. The company has experienced significant declines, with a year-to-date return of -100.0%, underperforming the S&P 500, which has returned 12.22% in the same period....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-67.57%
EBIT Growth (5y)
13.92%
EBIT to Interest (avg)
-11.14
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.34
Sales to Capital Employed (avg)
0.00
Tax Ratio
2.07%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
38.05%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.01
EV to EBIT
-0.60
EV to EBITDA
-0.61
EV to Capital Employed
-0.52
EV to Sales
36.76
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (2.43%)

Foreign Institutions

Held by 10 Foreign Institutions (0.24%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is -100.00% vs -40.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is -441.54% vs 254.76% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.30",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.10",
          "val2": "-15.70",
          "chgp": "-2.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "0.70",
          "chgp": "185.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "8.30",
          "val2": "13.00",
          "chgp": "-36.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-22.20",
          "val2": "6.50",
          "chgp": "-441.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-507,093.80%",
          "val2": "-49,641.50%",
          "chgp": "-45,745.23%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -100.00% vs -75.00% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -154.71% vs 72.66% in Dec 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.30",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-66.60",
          "val2": "-60.90",
          "chgp": "-9.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "9.80",
          "val2": "11.00",
          "chgp": "-10.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "14.90",
          "val2": "20.90",
          "chgp": "-28.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-124.30",
          "val2": "-48.80",
          "chgp": "-154.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-16,785,750.00%",
          "val2": "-202,560.70%",
          "chgp": "-16,58,318.93%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQstock-summary
Sep'24
Jun'24
Change(%)
Net Sales
0.00
0.30
-100.00%
Operating Profit (PBDIT) excl Other Income
-16.10
-15.70
-2.55%
Interest
2.00
0.70
185.71%
Exceptional Items
8.30
13.00
-36.15%
Consolidate Net Profit
-22.20
6.50
-441.54%
Operating Profit Margin (Excl OI)
-507,093.80%
-49,641.50%
-45,745.23%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2024 is -100.00% vs -40.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2024 is -441.54% vs 254.76% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
0.00
0.30
-100.00%
Operating Profit (PBDIT) excl Other Income
-66.60
-60.90
-9.36%
Interest
9.80
11.00
-10.91%
Exceptional Items
14.90
20.90
-28.71%
Consolidate Net Profit
-124.30
-48.80
-154.71%
Operating Profit Margin (Excl OI)
-16,785,750.00%
-202,560.70%
-16,58,318.93%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is -100.00% vs -75.00% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -154.71% vs 72.66% in Dec 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About Biora Therapeutics, Inc. stock-summary
stock-summary
Biora Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Progenity, Inc. is a biotechnology company. The Company is engaged in developing and commercializing molecular testing products and precision medicine. It applies multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics, to its molecular testing products and to the development of a suite of investigational ingestible devices and drug/device combinations designed to provide precise diagnostic sampling and drug delivery solutions. It offers integrated molecular tests and end-to-end support services that enable physicians to incorporate genetic testing into their office workflow and enables in ordering multiple tests from one source. The Company’s molecular tests are: Innatal Prenatal Screen, Preparent Carrier Test, Riscover Hereditary Cancer Test, Resura Prenatal Test for Monogenic Disease, and Anatomic and Molecular Pathology Tests. It is also developing an ingestible capsule platform designed to help diagnose and treat gastrointestinal (GI) disorders.
Company Coordinates stock-summary
Company Details
4330 La Jolla Village Dr Ste 200 , SAN DIEGO CA : 92122
stock-summary
Tel: 1 760 49415551 619 2282886
stock-summary
https://www.progenity.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."